Data-driven drug strategy

Over the last 30 years, Equinox Group has provided commercial strategy consulting to biopharmaceutical firms at all stages of R&D to ensure they are set up for success. Our proprietary and rigorous modeling techniques are fast, flexible, and cost-effective.

 
 
 
 

Curious Equinox Group views recent launches and emerging agents?

Check out our blog posts.

Our Take Blog
Enhertu regimen Figure (1).jpg
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Enhertu is poised to dominate first-line HER2+ breast cancer
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Read More →
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Xolair-Figure JPG.jpg
Xolair, Food allergy, Genentech, Novartis
Xolair for food allergies: effective therapy at a high price
Xolair, Food allergy, Genentech, Novartis
Read More →
Xolair, Food allergy, Genentech, Novartis
Leqembi-Figure.jpg
Leqembi, Aduhelm, donanemab, Alzheimer's Disease, Eisai, Biogen, Eli Lilly
Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price
Leqembi, Aduhelm, donanemab, Alzheimer's Disease, Eisai, Biogen, Eli Lilly
Read More →
Leqembi, Aduhelm, donanemab, Alzheimer's Disease, Eisai, Biogen, Eli Lilly
Evrysdi-figure.jpg
Zolgensma, Spinraza, Evrysdi, Biogen, Novartis, Roche, SMA Type 1, Spinal Muscular Atrophy
Evrysdi: A Potential Game-Changer for SMA Type 1 Patients
Zolgensma, Spinraza, Evrysdi, Biogen, Novartis, Roche, SMA Type 1, Spinal Muscular Atrophy
Read More →
Zolgensma, Spinraza, Evrysdi, Biogen, Novartis, Roche, SMA Type 1, Spinal Muscular Atrophy
Cost Benefit Yescarta CAR T post.png
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
CAR-T Outlook
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
Read More →
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
Risperidone-vs.-Ulatorant.jpg
ulotaront, Sunovion, Lybalvi, schizophrenia, risperidone, Alkermes
Prospects for ulotaront in schizophrenia
ulotaront, Sunovion, Lybalvi, schizophrenia, risperidone, Alkermes
Read More →
ulotaront, Sunovion, Lybalvi, schizophrenia, risperidone, Alkermes
Enhertu-vs.-Kadcyla.jpg
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Enhertu shows high clinical innovation in second-line metastatic breast cancer
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Read More →
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Keytruda-and-Lenvima-Figure.jpg
Keytruda, Merck, Eisai, Lenvima, RCC
Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC
Keytruda, Merck, Eisai, Lenvima, RCC
Read More →
Keytruda, Merck, Eisai, Lenvima, RCC
amivantamab figure jpeg.jpg
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Read More →
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Capture3.JPG
Prioritizing Indications: An Analytical Framework
Read More →
drivers.png
Trodelvy, TNBC, Gilead
Trodelvy: A New Option for Later Lines TNBC
Trodelvy, TNBC, Gilead
Read More →
Trodelvy, TNBC, Gilead
Onco Drivers.PNG
Monjuvi, lenalidomide, DLBCL, Incyte
Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL
Monjuvi, lenalidomide, DLBCL, Incyte
Read More →
Monjuvi, lenalidomide, DLBCL, Incyte
Two indications.PNG
Rozlytrek, Brain Mets, Xalkori, ROS1
Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study
Rozlytrek, Brain Mets, Xalkori, ROS1
Read More →
Rozlytrek, Brain Mets, Xalkori, ROS1
Drivers.JPG
Melanoma, Pfizer, Braftovi, Mektovi
Pfizer Combo Gains an Edge in BRAF+ Melanoma
Melanoma, Pfizer, Braftovi, Mektovi
Read More →
Melanoma, Pfizer, Braftovi, Mektovi
Drivers.JPG
Trikafta, Cystic Fybrosis, Vertex
Trikafta: A Major Step Forward for Cystic Fibrosis Patients
Trikafta, Cystic Fybrosis, Vertex
Read More →
Trikafta, Cystic Fybrosis, Vertex
A Reliable Predictor of NICE Recommendation
NICE
A Reliable Predictor of NICE Recommendation
NICE
Read More →
NICE
Table.JPG
Brukinsa, MCL, Mantle Cell Lymphoma
Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma
Brukinsa, MCL, Mantle Cell Lymphoma
Read More →
Brukinsa, MCL, Mantle Cell Lymphoma
Drivers website.JPG
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Lynparza: Expanding into Prostate Cancer
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Read More →
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Bubble chart.JPG
Keytruda, drug pricing, NSCLC
Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda
Keytruda, drug pricing, NSCLC
Read More →
Keytruda, drug pricing, NSCLC
drivers correct.JPG
Enhertu, breast cancer, AstraZeneca, HER2+
Enhertu: A New Leader in Later-Line Breast Cancer
Enhertu, breast cancer, AstraZeneca, HER2+
Read More →
Enhertu, breast cancer, AstraZeneca, HER2+
Zejula Updated.JPG
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
PARP Inhibitors: Promise in New Maintenance Indications
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
Read More →
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
now onco.png
Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model
Read More →
Capture.JPG
Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC
Read More →
Capture.JPG
drug pricing
Pricing a new oncology agent across multiple indications
drug pricing
Read More →
drug pricing
Drivers for Calquence.PNG
Calquence: The price is right
Read More →
radicava, ALS, edaravone, riluzole
Radicava: Not Innovative Enough to Sustain Strong Start
radicava, ALS, edaravone, riluzole
Read More →
radicava, ALS, edaravone, riluzole
dfsdf.png
How to Price an Oncology Drug
Read More →
Capture.JPG
Hemlibra, Hemophilia A, Advate, emicizumab
Hemlibra: A Strong Leader in Hemophilia A
Hemlibra, Hemophilia A, Advate, emicizumab
Read More →
Hemlibra, Hemophilia A, Advate, emicizumab
Capture.JPG
Oral semaglutide: A game changer in type 2 diabetes
Read More →
Tymlos, osteoporosis, ACTIVE, pharma
Tymlos: A new force in the osteoporosis market
Tymlos, osteoporosis, ACTIVE, pharma
Read More →
Tymlos, osteoporosis, ACTIVE, pharma